- Investor Information · Raising Now
A De-risked Clinical Asset in a Large Market
Lixumistat has completed Phase 1 with a clean safety profile and is showing early efficacy in the Phase 1b/2a PDAC trial. ImmunoMet is raising to complete the PDAC study and initiate GBM studies.
~$39M
Total Capital Raised, 2015–present
$10M
Current Raise Target
Founded 2015
Spin-off of Hanall Biopharma, Korea
Phase 2-Ready
Lixumistat Asset Status
~$39M
Total Capital Raised, 2015–present
$10M
Current Raise Target
Founded 2015
Spin-off of Hanall Biopharma, Korea
Phase 2-Ready
Lixumistat Asset Status
- Investment Thesis
Why ImmunoMet, Why Now
Lixumistat is the only clinical-stage OxPhos inhibitor with demonstrated efficacy in pancreatic cancer. Phase 1 is complete with a well-characterised safety profile. Phase 1b/2a is active at MD Anderson with a 50% response rate at the recommended dose.
The current raise funds the path to proof of concept in PDAC and GBM — two data inflection points that position ImmunoMet for partnering, licensing, or a next funding round.
Phase 1 Status
Published: Janku et al., Inv New Drugs, 2022
Phase 1b/2a Status
2015 to present
Next Indication
Window-of-Opportunity + Phase 2 planned
Raise target $10M confirmed in session transcript. ~$39M total raised confirmed in investor deck. Hanall Biopharma origin confirmed in session transcript.
- Get in Touch
Interested in Learning More?
For investor enquiries or to request the full investor deck, use the contact form.
